Pancreatic cancer has early but closely watched mRNA neoantigen vaccine research. Autogene cevumeran/BNT122/RO7198457 has been studied after surgery with atezolizumab and chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → in pancreatic ductal adenocarcinoma. Larger studies are testing whether vaccine-induced immune responses can translate into fewer recurrences or longer control. Phase 3 work focuses heavily on the dominant KRASOne of the most common cancer-driving mutations, found in lung, colon, and pancreatic cancers.Click for full explanation → pathway. Daraxonrasib (RMC-6236), a pan-RAS inhibitor, is in Phase 3 in previously treated metastatic PDAC. BMS-986504 added to gemcitabine plus nab-paclitaxel is being compared against placebo in untreated metastatic disease. The Phase 2 APOLLO trial tests olaparib maintenance after curative-intent therapy in patients with resected PDAC and pathogenic BRCA1Genes whose mutations significantly raise the risk of breast and ovarian cancers.Click for full explanation →, BRCA2Genes whose mutations significantly raise the risk of breast and ovarian cancers.Click for full explanation →, or PALB2 mutationsA change in DNA sequence that can drive cancer development.Click for full explanation →. Earlier work includes BNT327 (pumitamig), a PD-L1 and VEGF bispecific, with chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation →; pegcetacoplan added to modified FOLFIRINOX; the MK2 inhibitor zunsemetinib with mFOLFIRINOX; and CA-4948 added to standard chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation →. Theranostic radioligand pairs targeting integrins and somatostatin receptors are in early study, and ASP2138 for claudin 18.2-positive disease is in Phase 1. Cachexia, a major source of decline, is being addressed in trials of ponsegromab and nano-megestrol acetate. Laboratory work is uncovering KRASOne of the most common cancer-driving mutations, found in lung, colon, and pancreatic cancers.Click for full explanation → G12D inhibitor resistance through Fra-2, KRASOne of the most common cancer-driving mutations, found in lung, colon, and pancreatic cancers.Click for full explanation → G12R-specific signaling vulnerabilities, immunosuppressive damage-associated macrophages targetable via GPR34, hypoxia-driven IL-6 from fibroblasts, and tumor-reactive T-cell repertoires that may inform future immunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation →.
Where the evidence stands
Combination chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → regimens remain the standard and have been incrementally improved over the last decade. PARP maintenance for BRCAGenes whose mutations significantly raise the risk of breast and ovarian cancers.Click for full explanation → carriers and immunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation → for the rare MMR-deficient subgroup are established. Pan-KRASOne of the most common cancer-driving mutations, found in lung, colon, and pancreatic cancers.Click for full explanation → and KRASOne of the most common cancer-driving mutations, found in lung, colon, and pancreatic cancers.Click for full explanation → G12D inhibitors are the most-watched late-stage developments. Most other novel approaches, including immunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation → combinations, ADCs, radioligands, and stromal-targeted strategies, are in Phase 1 or 2. Cachexia drugs are advancing in mid-stage trials. Most laboratory findings remain years from the clinic.
What this means for people affected
Pancreatic cancer remains a field where standard chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → is the foundation and new treatments have not yet substantially shifted survival for most people. The exceptions are biomarkerA measurable biological signal used to detect disease or predict treatment response.Click for full explanation →-defined subgroups: BRCAGenes whose mutations significantly raise the risk of breast and ovarian cancers.Click for full explanation →, PALB2, MSI-high, NTRK or NRG1 fusion, and KRASOne of the most common cancer-driving mutations, found in lung, colon, and pancreatic cancers.Click for full explanation → G12C. Comprehensive molecular profiling, including germline testing, is reasonable at diagnosis of advanced disease because it occasionally identifies these treatable groups. The recent KRASOne of the most common cancer-driving mutations, found in lung, colon, and pancreatic cancers.Click for full explanation →-directed Phase 3 programs are the most consequential trials in the field, and clinical trialA research study that tests a medical intervention in human volunteers.Click for full explanation → enrollment is recommended in many guidelines because standard options remain limited. Supportive care for cachexia, pain, and symptom burden is an active research area and a meaningful part of treatment.
Last updated May 22, 2026
Recent research findings
Understanding evidence levels▼
PreclinicalLab or cell studies — no human data yet.
Animal StudyResults in animals only — may not apply to humans.
Phase 1 TrialFirst-in-human safety testing in small groups.
Phase 2 TrialEarly effectiveness testing in a larger group.
Phase 3 TrialLarge controlled trial — the strongest trial evidence.
Observational StudyPatterns observed in populations — not a controlled trial.
ReviewSummary analysis of multiple existing studies.
Meta-AnalysisStatistical pooling of results from multiple studies.
⚡ Major findingLater-stage evidence with especially strong reported efficacy, typically a phase 3 trial or meta-analysis.Phase 3 TrialLarge controlled trial comparing treatments. The strongest level of trial evidence.Published: August 14, 2026
Daraxonrasib Improves Survival in Pancreatic Cancer Patients
Researchers tested daraxonrasib in patients with pancreatic cancer that had spread and didn't respond to previous treatments. They found that daraxonrasib improved overall and progression-free survival compared to standard chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation →, but the results are not clear for patients with certain types of pancreatic cancer. The study only looked at patients with a specific type of genetic mutationA change in DNA sequence that can drive cancer development.Click for full explanation →.
Why it matters: This finding could help doctors choose the best treatment options for patients with pancreatic cancer and specific genetic mutationsA change in DNA sequence that can drive cancer development.Click for full explanation →.
Efficacy
The trial demonstrated significant overall and progression-free survival benefits with daraxonrasib over investigator's choice chemotherapy.
The benefit in patients with non-G12 RAS mutations or RAS wild-type tumors remains unclear.
Observational StudyPatterns observed in populations over time, not a controlled experiment.Published: August 12, 2026
Comparing Two Surgery Options for Pancreatic Cancer
Researchers compared two surgical procedures for pancreatic cancer: distal pancreatectomy with celiac axis resection and total pancreatectomy with celiac axis resection. They found that the second procedure was associated with higher complication rates and longer hospital stays, but no significant difference in survival rates.
Why it matters: This study provides insights into the risks and benefits of different surgical options for pancreatic cancer, which can inform treatment decisions.
Small sample size, with only 8 patients undergoing total pancreatectomy with celiac axis resection.
Observational StudyPatterns observed in populations over time, not a controlled experiment.Published: August 12, 2026
Timing of Third-Line Treatment for Advanced Pancreatic Cancer
Researchers studied when patients with advanced pancreatic cancer should start third-line treatment after stopping second-line treatment. They found that starting third-line treatment early might be beneficial, but the results are uncertain due to a small sample size.
Why it matters: This finding could help doctors make better decisions about when to start third-line treatment for patients with advanced pancreatic cancer.
Efficacy
Early initiation showed a directionally favorable but imprecise association with OS (aHR 0.40, 95% CI 0.15-1.04).
This study had a small sample size of 130 patients and used a 30-day landmark strategy, which may introduce biases.
Observational StudyPatterns observed in populations over time, not a controlled experiment.Published: August 12, 2026
Nutritional Risk Linked to Treatment Outcomes in Pancreatic Cancer
Researchers studied 120 patients with pancreatic cancer and found that those with a lower nutritional risk score before treatment were less likely to continue treatment and had more side effects. This suggests that nutritional status may play a role in treatment outcomes. However, more research is needed to confirm these findings.
Why it matters: This study highlights the importance of considering nutritional status when treating pancreatic cancer patients.
Efficacy
Each 1-point increase in GNRI was independently associated with second-line transition (odds ratio 1.08, 95% confidence interval 1.03-1.14) and longer overall survival (hazard ratio 0.96, 95% confidence interval 0.93-0.98).
Observational StudyPatterns observed in populations over time, not a controlled experiment.Published: August 11, 2026
Dignity Therapy May Help Patients with Advanced Cancer
Researchers tested a therapy called Dignity Therapy in patients with advanced pancreatic or gastric cancer who were undergoing chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation →. They found that patients experienced less emotional distress and dignity-related distress after receiving the therapy. However, the study was small and had some limitations.
Why it matters: This finding could help patients with advanced cancer feel more dignified and emotionally supported during their treatment.
Efficacy
Emotional distress decreased significantly from 6.67 to 3.13 (p < .001) and remained lower at 3.50 (p < .001). Dignity-related distress also decreased from 37.1 to 27.9 (p < .001), with sustained improvement at 25.4 (p < .01).
The study had a small sample size and lacked a control group.
Phase 1 TrialFirst-in-human trial. Focuses on safety and dosing in small groups.Est. completion: May 31, 2028
Testing a New Vaccine for Advanced Liver, Pancreatic, and Bile Duct Cancers
Researchers are studying a new vaccine called YMN-136 in patients with advanced liver, pancreatic, and bile duct cancers. The goal is to see if this vaccine is safe and can help the body's immune system fight these cancers. The trial is currently recruiting participants.
Why it matters: This trial may help doctors understand if the YMN-136 vaccine can be a useful treatment option for people with advanced liver, pancreatic, and bile duct cancers.
Phase 2 TrialTests early effectiveness in a larger group after phase 1 safety is established.Est. completion: December 31, 2026
Testing Gemcitabine and Nab-Paclitaxel for Metastatic Pancreatic Cancer
This clinical trialA research study that tests a medical intervention in human volunteers.Click for full explanation → is studying the effectiveness of a specific treatment schedule for metastatic pancreatic cancer. The trial is currently active but not recruiting participants. Researchers are investigating whether this treatment combination can help patients with this type of cancer.
Why it matters: This trial may provide valuable information about the treatment of metastatic pancreatic cancer.
ReviewSummary and analysis of existing published studies.Published: August 10, 2026
New Cancer Vaccine Approach Uses mRNA Technology
Researchers studied a new type of cancer vaccine that targets specific genetic mutationsA change in DNA sequence that can drive cancer development.Click for full explanation → in tumors. They found that this approach can be effective, but more research is needed to understand its full potential. The vaccine uses mRNA technology to encode multiple patient-specific epitopes in a single product.
Why it matters: This finding could lead to more personalized and effective cancer treatments in the future.
The review is based on single-arm and early-phase trials in heterogeneous tumor types.
Phase 3 TrialLarge controlled trial comparing treatments. The strongest level of trial evidence.Est. completion: December 31, 2032
Exercise Study for Pancreatic Cancer Patients
This trial is studying whether video-based strengthening exercises can help patients with resectable pancreatic cancer before surgery. Participants will receive either standard care or tele-supervised resistance exercises. The trial is currently active but not recruiting participants.
Why it matters: This trial aims to improve the health and well-being of patients with pancreatic cancer through exercise.
⚡ Major findingLater-stage evidence with especially strong reported efficacy, typically a phase 3 trial or meta-analysis.Phase 3 TrialLarge controlled trial comparing treatments. The strongest level of trial evidence.Published: August 8, 2026
New Treatment Shows Promise for Pancreatic Cancer Patients
Researchers tested a new treatment called daraxonrasib in patients with advanced pancreatic cancer. They found that it nearly doubled the time patients lived without their cancer getting worse compared to standard chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation →. This is an early study, and more research is needed to confirm these results.
Why it matters: This finding could lead to new treatment options for patients with advanced pancreatic cancer.
Efficacy
Median overall survival was 13.2 months with daraxonrasib, compared to 6.6 months with chemotherapy.
PreclinicalLab or cell studies. No human data yet.Est. completion: January 31, 2032
Pilot Study of Pancreatic Cancer Screening Methods
This trial is studying different methods for screening pancreatic cancer. Researchers are collecting biospecimens, using imaging tests like MRI and endoscopic ultrasound, and asking participants questions. The trial is currently active but not recruiting participants.
Why it matters: This trial aims to help develop more effective methods for detecting pancreatic cancer early, when it may be easier to treat.
The trial is not recruiting participants and its exact phase is not specified.
Phase 2 TrialTests early effectiveness in a larger group after phase 1 safety is established.Est. completion: June 30, 2028
Imaging Test for Pancreatic Cancer
This clinical trialA research study that tests a medical intervention in human volunteers.Click for full explanation → is studying a new imaging test called 68Ga-FAPI-46 PET/CT to see if it can help doctors identify cancer-associated fibroblasts in patients with localized pancreatic ductal adenocarcinoma. The trial is currently recruiting participants. The results of this trial are not yet available.
Why it matters: This trial may help doctors develop a more accurate way to diagnose and monitor pancreatic cancer.
A Phase 2 Study of VS-7375 in Patients With KRASOne of the most common cancer-driving mutations, found in lung, colon, and pancreatic cancers.Click for full explanation → G12D-Mutated Pancreatic Cancer
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1Genes whose mutations significantly raise the risk of breast and ovarian cancers.Click for full explanation →, BRCA2Genes whose mutations significantly raise the risk of breast and ovarian cancers.Click for full explanation → or PALB2 MutationA change in DNA sequence that can drive cancer development.Click for full explanation →
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
